The interleukin (IL)−1 → IL-6 → C reactive protein (CRP) axis has been suggested to play an important role in cardiovascular inflammation.3 Elevated CRP predicts future coronary events and is associated with worse outcomes in acute coronary syndromes.4 5 Moreover, the landmark Canakinumab Anti-Inflammatory Thrombosis Outcome Study showed that IL-1β inhibition reduces the risk of future cardiovascular events in patients with previous MI and residual inflammatory risk defined as CRP>2 mg/L. This evidence concerns the gene CRP and myocardial infarction.